362706-25-0 Usage
General Description
1-BOC-5-Methyl-3-pyrrolidinone is a chemical compound with the formula C10H17NO3. It is a derivative of 3-pyrrolidinone with a tert-butyloxycarbonyl (BOC) protecting group at the nitrogen atom and a methyl group at the 5-position. 1-BOC-5-Methyl-3-pyrrolidinone is commonly used as a reagent for chemical synthesis, particularly in the field of organic chemistry. It is known for its high reactivity and versatility, making it useful in a wide range of reactions and processes. Additionally, 1-BOC-5-Methyl-3-pyrrolidinone is considered relatively stable and easy to handle, making it a popular choice for synthetic procedures. Overall, this compound plays a crucial role in the development and production of various organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 362706-25-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,2,7,0 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 362706-25:
(8*3)+(7*6)+(6*2)+(5*7)+(4*0)+(3*6)+(2*2)+(1*5)=140
140 % 10 = 0
So 362706-25-0 is a valid CAS Registry Number.
362706-25-0Relevant articles and documents
DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS
-
Page/Page column 84, (2014/04/04)
The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERKl and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics
Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
-
, (2008/06/13)
The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-α inhibitors.
